The ARUP Institute for Learning is committed to supporting educational events that advance the practice of laboratory medicine and improve quality patient care by providing guest speakers at local and regional meetings. Listed below are the current events where the Institute for Learning is providing sponsored speakers.
Marc Roger Couturier, PhD, D(ABMM)
Medical Director, Microbial Immunology
Medical Director, Parasitology and Fecal Testing
Medical Director, Infectious Disease Rapid Testing
Shigatoxigenic E. coli: A Fully Emerged, Still-Underappreciated Pathogen
Shigatoxigenic E. coli (STEC) is an enteric pathogen associated with several foodborne infections throughout the world every year. The major virulence determinant that defines STEC is the shiga-like toxin which is capable of transmission between various gram-negative organisms. STEC causes significant morbidity during acute outbreaks, and can cause mortality associated with the development of hemolytic uremic syndrome. Until recently, testing for STEC in the clinical laboratory was inadequate, relying solely on selective, serogroup-biased culture methods. Recent advancements have been made which allow for toxin detection or molecular detection of toxin genes from stool specimens, removing the culture bias problem. With these improvements in screening, the cases of STEC reported have increased significantly; revealing a pathogen that may have eluded the laboratory for decades. The 2011 STEC outbreak in Germany will be discussed in detail as an example of the emerging nature of this enigmatic pathogen.
Helicobacter pylori: Update on Disease, Diagnosis and Discouraging Trends
Helicobacter pylori is one of the most common bacterial infections worldwide, with infection rates upwards of 50% of the human population. While most of these infections are asymptomatic, a significant number of patients will develop severe disease due to this bacterial pathogen, including serious life threatening gastric cancers. The testing strategy for Helicobacter pylori will be reviewed, with particular focus on the non-invasive mechanisms of testing that are central to the clinical pathology laboratory and consistent with guidelines issues by multiple professional organizations. Finally, challenges related to proper test utilization and treatment failures will be discussed.
David G. Grenache, PhD
Medical Director, Special Chemistry
Co-Medical Director, Electrophoresis/Manual Endocrinology
Section Chief, Chemistry
Screening for Gestational Diabetes Mellitus: Challenges and Controversies
Gestational diabetes mellitus (GDM) is associated with several adverse outcomes for the fetus, newborn, and mother. Evidence clearly shows that identifying and treating pregnant women with GDM ameliorates poor outcomes. There continues to be controversy regarding the most appropriate methods to screen for and diagnose GDM. This presentation will describe the controversies in GDM testing and review the current evidence regarding the various screening recommendations.
The Clinical Chemistry of Pregnancy
Normal pregnancy is associated with a multitude of physiological adaptations. Although most pregnancies progress without complications, problems can arise in the mother, fetus, or placenta. This presentation describes normal pregnancy-related physiological changes and several disorders that are associated with pregnancy that can affect laboratory test results.
David R. Hillyard, MD
Medical Director, Molecular Infectious Diseases
The Changing Landscape of Hepatitis C Testing and Therapy
The discovery, diagnosis, and treatment of the hepatitis C virus (HCV) rank as one of modern medicine’s great accomplishments. At each stage of the HCV revolution, laboratory testing has been key to foundational research, identification of chronically infected patients, and rational guidance of evolving therapies. Recent initiatives for comprehensive screening and the availability of new well-tolerated, highly effective therapies have galvanized the public’s attention as never before.
This video lecture will review the evolving role of laboratory testing in the diagnosis and management of chronic HCV infection, focusing on current guidelines and test resources. It will also address expected public health outcomes and issues in this era of the HCV cure.